Sun Yidan, Zhang Ying, Ren Shiqi, Li Xiaojiang, Yang Peiying, Zhu Jinli, Lin Lisen, Wang Ziheng, Jia Yingjie
Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, PR China; Department of Oncology, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, PR China.
Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, PR China.
Int Immunopharmacol. 2020 Jun;83:106454. doi: 10.1016/j.intimp.2020.106454. Epub 2020 Apr 4.
Lung adenocarcinoma (LUAD) is a frequently diagnosed histologic subtype with increasing morbidity and mortality. RalGDS-Like 4 (RGL4) has not been reported to be associated with cancer risk, prognosis, immunotherapy or any other treatments. We perform a bioinformatics analysis on data downloaded from the Cancer Genome Atlas (TCGA)-LUAD, and we find that low expression of RGL4 is accompanied by worse outcomes and prognosis in LUAD patients. As a promising predictor, the potential influence and mechanisms of RGL4 on overall survival are worth exploring. Moreover, RGL4 expression is significantly associated with a variety of tumor-infiltrating immune cells (TIICs), particularly memory B cells, CD8T cells and neutrophils. Subsequently, we evaluated the most notable KEGG pathways, including glycolysis gluconeogenesis, the P53 signaling pathway, RNA degradation, and the B cell receptor signaling pathway, among others. Our findings provide evidence that the decreased expression of RGL4 is significantly associated with poor prognosis and immune cell infiltration in patients with LUAD and highlight the use of RGL4 as a novel predictive biomarker for the prognosis of LUAD and other cancers. RGL4 may also be used in combination with immune checkpoints to identify the benefits of immunotherapy. Subjects: Bioinformatics, Genomics, Oncology, Thoracic surgery.
肺腺癌（LUAD）是一种常见的组织学亚型，其发病率和死亡率不断上升。尚未有报道称类RalGDS-4（RGL4）与癌症风险、预后、免疫治疗或任何其他治疗相关。我们对从癌症基因组图谱（TCGA）-LUAD下载的数据进行了生物信息学分析，发现LUAD患者中RGL4低表达伴随着更差的结局和预后。作为一个有前景的预测指标，RGL4对总生存期的潜在影响和机制值得探索。此外，RGL4表达与多种肿瘤浸润免疫细胞（TIIC）显著相关，尤其是记忆B细胞、CD8 T细胞和中性粒细胞。随后，我们评估了最显著的KEGG通路，包括糖酵解/糖异生、P53信号通路、RNA降解和B细胞受体信号通路等。我们的研究结果提供了证据，表明RGL4表达降低与LUAD患者的不良预后和免疫细胞浸润显著相关，并突出了将RGL4用作LUAD和其他癌症预后的新型预测生物标志物。RGL4也可与免疫检查点联合使用，以确定免疫治疗的益处。主题：生物信息学、基因组学、肿瘤学、胸外科。
